Moderna effect and time for commercialized
Biden and Trump's Position
Moderna Corona19 Vaccine
"The new coronavirus infection (Corona 19) vaccine under development has shown 94.5 percent efficacy in clinical three-phase tests," said U.S. biotech company Moderna on Wednesday (local time). Earlier on the 9th, large U.S. pharmaceutical company Huizawa and Germany's Bioentech announced that the vaccine being jointly developed showed more than 90 percent efficacy in clinical trials.
Although it is an interim analysis, global pharmaceutical companies have released a series of positive results, raising expectations that the timing of mass production and inoculation of the Corona 19 vaccine could be accelerated. Moderna announced the results of its analysis of 95 people with corona19 in a three-phase test conducted on about 30,000 participants.
While 90 cases of corona infection were found in the group of participants who were given placebo (plasebo) without vaccination, only five cases were reported in the group that received the vaccine candidate substance twice. Moderna added that its vaccine can be stored for 30 days at 2 to 8 degrees Celsius and for six months at minus 20 degrees Celsius. The vaccines of Huizawa Bioentech should be distributed at ultra-low temperatures of minus 70 degrees. Moderna said it will request approval from the U.S.
Food and Drug Administration within the next few weeks, adding that it will supply 20 million doses of vaccines (a total of 10 million people) to Americans within this year. "We have produced positive results in the third phase, and we have the first clinical result that the vaccine we made can prevent Corona19. We believe this vaccine will be a game changer that changes the Corona19 landscape," said CEO Stephen Bangcell Moderna.
However, the announcement was made through the company's press release, not through a science journal, and some point out that Moderna carefully looks at the effectiveness of the vaccine, given that it did not disclose specific data to verify the effectiveness of the vaccine. Moderna, a U.S. pharmaceutical company, has started developing a new coronavirus infection (Corona 19) vaccine in collaboration with researchers at the vaccine research center at the National Institute of Allergy and Infectious Diseases.
In July this year, the company began testing the Corona 19 vaccine phase 3 with the U.S. Pfizer-German Biogentech and the University of AstraZeneca-Oxford in the U.K. About 30,000 Americans over the age of 18 were given placebo and vaccines.
According to the company, only five of the participants who received the vaccine were tested positive for Corona 19. Symptoms are also known to be mild. On the other hand, 90 participants were infected with corona 19 and 11 were critically ill. Following Huaiza, which said it had confirmed more than 90 percent of the efficacy in clinical trials, Moderina also said it had confirmed 94.5 percent of the efficacy, experts said, adding that they were encouraging.
Anthony Fauchy, director of the National Institute of Allergy and Infectious Diseases, who co-developed vaccines with Moderna, said, "We have said that we would be satisfied with only 75 percent of the vaccine's effectiveness, and we hoped for a 90 to 95 percent vaccine, but we didn't expect it, but the 94.5 percent figure is very impressive. Moderna has announced plans to supply 10 million doses of vaccines within this year.
Above all, the advantage is that moders and vaccines can be refrigerated. Moderas and vaccines were made using messenger ribonucleic acid (mRNA) as well as the pfizer vaccine. By administering mRNA directly to patient cells to produce certain proteins, it is induced to treat diseases caused by protein deficiency, or to produce antibodies directly against infectious sources. In particular, it can be stored for two to eight degrees for 30 days and for six months at minus 20 degrees, according to Moderna.
In the case of the pfizer vaccine, it is known to be effective only if it is stored in an ultra-low temperature environment of minus 70 degrees Celsius and can be stored in the refrigerator for up to five days. Currently, there is no place in the world with an ultra-low temperature vaccine distribution network. Mass inoculation of the pfizer vaccine requires the establishment of a distribution network at a huge cost. Nevertheless, it is expected that the timing of mass inoculation will be advanced a little bit if safety is secured in the future as Modena has released positive results following Huiza.
However, some say that it is too early to be optimistic in that it is only an interim result and based on the company's announcement. "We have to wait and see until more people are inoculated," said Jung Ki-seok, a respiratory physician at Hallym University Sacred Heart Hospital. The New York Times (NYT) said, "The clinical test is in progress, and the figures on the effectiveness of the vaccine may change. It will take months to reach the public next spring," he predicted.
Biden's view
U.S. President-elect Joe Biden said he would not hesitate to vaccinate Corona. He also called for President Donald Trump's cooperation, saying more people will die if the transition process is delayed. It is also seen as a sign of frustration that if the Korona 19 response is not coordinated properly due to President Trump's dissatisfaction with the outcome of the presidential election and the obstacles to the transition team's activities, it will cause more damage.
According to AFP, when asked by the media what was the biggest threat to President Trump's obstruction of power transfer after his economic initiative speech, Biden replied, "If we don't coordinate, more people may die." "If we have to wait until Jan. 20 to start planning, it will leave us a month or a half behind," he said. "It is important to coordinate now so that we can do it as quickly as possible," he reiterated and called for access and coordination to the vaccination plan. He said that President Trump's non-cooperation is embarrassing and that it is "more embarrassing for this country than weakening what my ability starts."
He also said he has been in contact with Republican figures but has been hesitant to cooperate because of President Trump's dissatisfaction, adding, "It's a shame if we have to wait until Jan. 20, but that may be the only way." Biden said he would not hesitate to get vaccinated if the vaccine was deemed safe. Biden tweeted, "The news of the second vaccine (after Huiza) is another reason to feel hope." He also urged the U.S. people to limit the number of people who gather during Thanksgiving, while also calling for social distance and wearing masks.
Trunps's Operation Wrap Speed
On the other hand, Moderna signed a contract while Trump was in office. Operation Warp Speed (OWS) is a public-private partnership project initiated by the U.S. government under the Trump administration to promote and accelerate the development, manufacture and dissemination of COVID-19 vaccines, treatments and diagnostics. Operation Warp Speed was introduced in early April 2020 after a roundtable meeting with industry executives at the White House on March 2.
If one of the vaccines is confirmed to be safe and effective as a result of clinical trials, the company will push for mass production of multiple vaccines based on prior evidence to enable faster distribution. The plan expects that some of these vaccines will be either safe or ineffective, which will cost the program more than the general vaccine development, but potentially lead to the availability of a viable vaccine several months earlier than the usual schedule.
The U.S. Congress allocated nearly $10 billion for warp speed operations under the CARES Act (Coronavirus Assistance Act, Relief Act, Economic Security Act) on March 27, $6.5 billion and $3 billion for NIH research, which Congress designated to develop measures through the BARDA.
댓글